Closed - October 6, 2026 at 5:00 PM local applicant-organization deadline passed.Atlas Opportunity Score 93/100
NIH/NIDDK — Advancing Digital Health Technology for Type 2 Diabetes (RFA-DK-26-315)
Open NIH/NIDDK R01 clinical-trial opportunity for digital-health approaches to type 2 diabetes management. Applications are due October 6, 2026 at 5:00 PM applicant-local time. Atlas rates N9+ fit as high where connected examination and telehealth workflows are part of a rigorous applicant-led study.
FundingApplication budgets are not limited but must reflect actual project needs. The NOFO anticipates three grants and describes institute funding availability across the award period.
DeadlineOctober 6, 2026 at 5:00 PM local time of the applicant organization.
Last verifiedOctober 7, 2026
Required next actionApplicants that submitted by the October 6, 2026 deadline should monitor Grants.gov and eRA Commons for validation, review, and agency communications. Other eligible research teams should monitor NIDDK and the NIH Guide for successor digital-health and diabetes research opportunities.
Broad Eligibility
The NIH NOFO permits multiple domestic organization types subject to the full eligibility rules, registrations, and clinical-trial requirements. Applicants must be able to conduct the required R01 clinical trial and complete NIH/Grants.gov/eRA Commons registrations.
Atlas Analysis
Atlas Opportunity Score 94/100. High-value NIH R01 clinical-trial opportunity focused on evaluating digital-health approaches for type 2 diabetes management. Competitive applicants need credible scientific leadership, diabetes expertise, clinical-trial capability, appropriate human-subjects protections, and a study design that directly addresses the NOFO objectives. Application budgets are not capped but must be justified by the proposed work.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH, is accepting R01 clinical-trial applications under RFA-DK-26-315 to evaluate digital-health approaches for managing type 2 diabetes.
Deadline: October 6, 2026 at 5:00 PM local time of the applicant organization. The NOFO requires a clinical trial and lists three anticipated grants. Application budgets are not capped but must reflect actual project needs; the maximum project period is five years.
Atlas fit: High. The funded scope directly supports evaluation of digital-health approaches to diabetes management, making connected clinical examination, vitals capture, telehealth-enabled encounters, and care-team workflows potentially relevant when embedded in a rigorous applicant-led research design. N9+ should be positioned as an existing deployable clinical technology supporting the study, not as an unsupported add-on.
Dr. Miltie may have a legitimate technology/vendor or research-partner role with an experienced clinical-trial applicant. Any direct-applicant strategy must independently satisfy NIH eligibility, research, registration, personnel, and clinical-trial requirements.
Source verificationOfficial government source · grants.nih.govAtlas last verified this record October 7, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
